Brief: Xoma Corp says Novartis Pharma AG Communicated To Co, It Intends To Discontinue Development Activities Related To Nis793

Xoma Royalty

25/08/2023 22:25

Aug 25 (Reuters) - XOMA Corp  XOMA.O :
    * XOMA CORP - NOVARTIS PHARMA AG COMMUNICATED TO CO THAT IT
INTENDS TO DISCONTINUE DEVELOPMENT ACTIVITIES RELATED TO NIS793
    * XOMA CORP - NOVARTIS TO CEASE ENROLLING PATIENTS IN
REMAINING
ACTIVE TGFß CLINICAL STUDIES AND WILL COLLECT ALL DATA UPON
CONCLUSION OF THESE STUDIES
    * XOMA CORP SAYS THERE IS NO GUARANTEE THAT NIS793 WILL
BECOME
COMMERCIALLY AVAILABLE

Further company coverage:  XOMA.O 

 ((Reuters.Briefs@thomsonreuters.com;))